CSIMarket Company Name, Ticker, Suppliers, else..
 
Apogee Therapeutics Inc   (NASDAQ: APGE)
 
Price: $135.0700 $0.00 0.000%
Day's High: $135.07000732421875 Week Perf: 0.07 %
Day's Low: $ 135.07 30 Day Perf: 0.63 %
Volume (M): 0 52 Wk High: $ 137.69
Volume (M$): $ 0 52 Wk Avg: $83.30
Open: $135.07 52 Wk Low: $35.39



 Market Capitalization (Millions $) 10,190
 Shares Outstanding (Millions) 75
 Employees 261
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -294
 Cash Flow (TTM) (Millions $) 327
 Capital Exp. (TTM) (Millions $) 0

Business Description


Apogee Therapeutics Inc. is a biotechnology company focused on the development of novel therapeutics for the treatment of various diseases. The company specializes in the discovery and development of small molecule drugs targeting specific biological pathways involved in disease processes. Apogee's goal is to create innovative and effective treatments that address unmet medical needs and improve patient outcomes. The company employs advanced technologies and collaborations with academic and industry partners to accelerate the development of their therapeutic candidates. Overall, Apogee Therapeutics aims to make a significant impact on the field of medicine by bringing new and improved treatments to patients worldwide.


   Company Address: 221 Crescent St Waltham 2453 MA
   Company Phone Number: 394‑5230   Stock Exchange / Ticker: NASDAQ APGE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
IBRX        1.3% 
IVVD   -16.97%    
MRNA        5.82% 
STRO   -3.61%    
TIL   -2.54%    
VXRT   -1.5%    
• View Complete Report
   



Clinical Study

Apogee Therapeutics Set to Showcase Promising Results from APG777 Phase 2 Trial at EADV 2025

Published Thu, Sep 11 2025 12:20 PM UTC

In a significant development for the treatment of moderate-to-severe atopic dermatitis, Apogee Therapeutics, Inc. (Nasdaq: APGE) has announced the acceptance of late-breaking data from its Phase 2 APEX trial of APG777 for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress, set to take place in Paris from September 17 to 20, 2025. Thi...
Clinical Study

- The landscape of therapeutic interventions for respiratory and inflammatory c...

Published Mon, Dec 30 2024 9:41 AM UTC

Title : Advancements in Respiratory Therapeutics: Apogee Therapeutics Doses First Participants in Phase 1 Clinical Trial of APG333 The landscape of therapeutic interventions for respiratory and inflammatory conditions has witnessed a significant advancement with the recent announcement by Apogee Therapeutics Inc. (NASDAQ: APGE) regarding the initiation of dosing in their ...
Product Service News

Apogee Therapeutics Pioneering a New Era in Inflammation & Immunology

Published Mon, Nov 18 2024 12:30 PM UTC

Revolutionizing Inflammation and Immunology: Insights from Apogee Therapeutics’ Upcoming Virtual R&D Day In an era where innovation in drug development remains pivotal, Apogee Therapeutics is poised to make significant strides in the field of Inflammation and Immunology (I&I). As the company prepares for its inaugural virtual R&D day on December 2, 2024, it aims to highlig...
Clinical Study

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Published Wed, May 15 2024 8:01 PM UTC

Apogee Therapeutics Initiates Phase 2 Clinical Trial of APG777 for Atopic Dermatitis Following Promising Phase 1 Results Apogee Therapeutics recently announced the commencement of dosing in their Phase 2 clinical trial for APG777, a novel subcutaneous, half-life extended anti-IL-13 antibody. This drug is being investigated for the treatment of atopic dermatitis and oth...
Clinical Study

Apogee Therapeutics Breaks Ground with Promising Drug Pipeline and Strong Q1 2024 Performance: Eagerly Awaits Game-Changing Data for Atopic Dermatitis Treatment

Published Mon, May 13 2024 11:00 AM UTC

Apogee Therapeutics Advances Promising Drug Pipeline and Acknowledges Strong First Quarter 2024 Financial Performance: Anticipates Key Data Release for APG777 in Late 2025Apogee Therapeutics, a leading biopharmaceutical company, is making remarkable progress in its pursuit of innovative therapies for patients suffering from debilitating conditions. The company recently annou...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 8.53
PEG (TTM) -

Financial Strength Current
Quick Ratio 25.91
Working Capital Ratio 26.8
Leverage Ratio (MRQ) 1.12
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -4.45 $
Revenues (TTM) -
Cash Flow (TTM) 4.34 $
Cash 12.88 $
Book Value 15.83 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,127,866
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -


  Apogee Therapeutics Inc Outlook

On May 13 2024 the Apogee Therapeutics Inc provided following guidance

Apogee Therapeutics Inc. has made significant progress in its pipeline, including the initiation of a Phase 2 clinical trial for APG777. This drug is a subcutaneous half-life extended monoclonal antibody that targets IL-13 and is being tested in patients with moderate-to-severe atopic dermatitis. The company expects to receive 16-week proof-of-concept data from Part A of the trial in the second half of 2025. This trial marks a significant milestone for Apogee Therapeutics as it continues to advance its pipeline of innovative therapies.

Additionally, Apogee Therapeutics reported its first quarter financial results for 2024. The company remains optimistic about its financial outlook and is committed to...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.